American and 20 out of 180 (11.1%) were AA. 91 out of 180 (50.6%) indicated that the highest level of education in their immediate family was some college credit, no degree. 91 out of 179 (50.8%) respondents have had >2 sexual partners, and 134 out of 180 (74.4%) used condoms. 25 out of 179 (14.0%) had not been sexually active. 3 out of 180 (1.7%) had experienced genital warts and 9 out of 131 (6.9%) had been diagnosed with cervical cancer. 36 out of 180 (20.0%) indicated that they had "no knowledge" of HPV. 95 out of 180 (52.8%) received the HPV vaccine, 44 out of 180 (24.4%) had not and 41 out of 180 (22.8%) did not know. 106 out of 180 (58.9%) participants did not know that the HPV vaccine is recommended for women and men through age 26, and 89 out of 180 (49.4%) did not know that they can get the HPV vaccine at the college student health center or youth friendly clinics.
Background. Human papillomavirus (HPV) vaccine uptake is suboptimal in the United States. School-based health centers (SBHCs) could improve rates of uptake by making HPV vaccination available in schools and more accessible and convenient to adolescents and families. To explore the potential of SBHCs to expand HPV vaccine uptake, we sought to determine whether a pilot program to actively promote the SBHC as a venue for HPV vaccine receipt could improve HPV vaccination status.
Methods. A pilot program aimed at increasing HPV vaccine uptake was implemented at a SBHC affiliated with a hospital-based primary care center (PCC) between October 2016 and June 2017. This SBHC is located in a high school and provides vaccination services, including HPV vaccine, but no systematic protocol existed to actively identify, and target for vaccination, patients who accessed clinical services at the PCC and were also enrolled in the SBHC. Immunization status of adolescents enrolled in the SBHC who were also patients of the PCC was screened by review of the common electronic health record (EHR) that is shared between both sites. Patients were eligible for inclusion if they were in need of ≥1 dose of HPV vaccine. Eligible patients were contacted by clinic staff and offered the opportunity to receive HPV vaccine at the SBHC in accordance with usual clinic practices.
Results. Of 86 patients screened, 13 were found to be eligible for HPV vaccination at the SBHC (Figure 1 ). By the end of the project period, 62% of those eligible had received ≥1 dose of HPV vaccine (n = 8) and 38% (n = 5) also received another vaccine (flu, meningococcal) at the same time as HPV vaccination.
Conclusion.
A pilot program consisting of determining HPV immunization status and actively offering the opportunity to receive needed doses of HPV vaccine at a SBHC resulted in improvement of vaccination status among eligible patients. Success was limited by the relatively small number of patients identified. While SBHCs may be one strategy to address missed opportunities for HPV vaccination, lack of centralized immunization records among patients who receive care from multiple providers and processes to directly communicate with parents about vaccination during school hours were identified as primary challenges. Background. Term and preterm infants in the neonatal intensive care unit (NICU) should be immunized at the same chronological age and on the same schedule as healthy term infants, but are often under-immunized. Reasons for under-immunization in this population have not been well-defined. The aim of this study was to assess the immunization rates of hospitalized term and preterm infants in the NICU and examine reasons for under-immunization.
Methods. Pharmacy and NICU databases were utilized to determine the immunization rates of eligible babies admitted to the NICU between 2011 and 2015. A retrospective review of unimmunized infants was undertaken to identify barriers to timely immunization. Patient demographics and transfers to other hospitals were recorded. Reasons for the delay in immunization were evaluated by detailed review of the hospital medical record.
Results. Of the 3,261 babies admitted to the NICU during the study period, 534 (16%) were hospitalized at ≥8 weeks of age, when first immunizations are administered. Of these, 142 (27%) received no immunizations in hospital. Sixty-five medical records were reviewed in detail. Thirty of the 65 (46%) medical records did not document that immunizations were due. In 21 (32%) of the 65 cases, there was no clear reason for lack of immunization. Of the remaining cases, infants were not vaccinated for 1 or more reasons. Infants deemed too unwell, including recovery from surgery, seizures/encephalopathy, severe immunocompromise, or palliative care, was one of the reasons for lack of vaccination in 35 (54%) of the 65 cases, parental refusal of vaccinations in 8 (12%) of cases, and deferral to discharging hospital in 7 (11%) of cases.
Conclusion. Significant comorbidity appeared to be the major reason behind vaccination delays, with 27% of highly vulnerable infants unimmunized. Significant improvements are required to ensure these babies receive vaccines upon recovery from their illness, and to ensure absence of immunization is clearly documented upon hospital discharge.
Disclosures. All authors: No reported disclosures. The ACIP has recommended that all children receive 2 doses of measles mumps rubella (MMR) and varicella (V) vaccines on the same schedule, with the first dose at 12-15 months and second dose at 4-6 years and that MMRV vaccine could be used for each dose. Post-licensure studies suggested a small increased rate of febrile seizure when MMRV is used as the first dose vs. MMR+V. In 2009, the ACIP revised its guidance to recommend separate injections of MMR+V for the first dose unless the parent or caregiver expressed a preference for MMRV. The objective of this study was to evaluate patterns of coverage and product utilization between 2006 and 2016.
Timeliness of Childhood Vaccination With the Combination Measles
Methods. This was a retrospective study of health insurance claims data in the MarketScan® Commercial Claims and Encounters Database from 2006 to 2016. Two cohorts were defined: children eligible for vaccination with continuous enrollment during ages 12-23 months (first dose cohort), and/or 4-7 years (second dose cohort). The primary outcome measures were vaccine coverage for first (by 19 months) and second (by 7 years) doses, percent with delays in vaccination, and length of vaccine delay.
Results. The analysis included 850,779 and 1,403,139 children in the 1st and second dose cohorts, respectively. Of the children in each dose cohort (1st/second), 7%/14% received MMRV vaccines, 77%/62% received MMR and/or V, and 17%/24% had no records of receiving any of the vaccines by the milestone age. Of those receiving MMR and/or V vaccines, 9%/21% were missing one of the two vaccines, 70%/65% had both on the same day, and 21%/14% received them on different days with median delays of 3 months/1 year (first/second dose, respectively).
Conclusion. MMRV vaccine is used infrequently as a first dose in this commercially insured population. Despite the ACIP recommendation to use MMRV for second dose, this vaccine is underutilized; use of MMR and V instead may result in delayed vaccination. Increased use of MMRV vaccines for the second dose between 4 and 6 years of age has the potential to improve vaccine compliance and coverage, and reduce the number of physician office visits. Background. Maintaining high coverage of measles, mumps, and rubella (MMR) vaccination is important for preventing outbreaks and maintaining herd immunity (HI), which benefits both individuals and communities. We aimed to determine whether information about the benefits of HI and local MMR vaccination rates could change a parent's concern about their child's risk of contracting measles.
Methods. We conducted a survey at the 2016 Minnesota State Fair among Minnesota residents ≥18 years who had at least one child aged 6-18 years. Participants were asked to choose the correct definition of HI, to estimate the MMR vaccination coverage in their county, and guess the minimum MMR vaccination coverage needed to prevent measles outbreaks. We delivered an educational intervention through the interactive survey informing participants about the benefits of herd immunity, the actual MMR coverage in their county, and that ≥95% coverage is needed to prevent outbreaks. Before and after the educational intervention, participants were asked to report their level of concern about their child contracting measles. We calculated adjusted predicted percentages from logistic regression models to evaluate changes in concern about risk pre-and post-intervention and to assess factors associated with concern about measles.
Results. Among the 493 participants, 92.7% reported vaccinating their child with MMR, though one third were not familiar with HI. Prior to receiving information, those knowledgeable about HI were significantly more likely to be concerned about their child getting measles (predicted percentage 80.2% [95% CI: 75.7-84.6]) than those who were unfamiliar with HI (predicted percentage 69.8% [95% CI: 62.1-77.5]), P-value for the difference = 0.027. Participants believed that MMR vaccination was, on average, 9.0% [95% CI: 6.9-11.0] lower than the actual coverage in their local area.
Conclusion. Information about HI and local vaccination coverage rates did not impact parental concern about their child being at risk for getting measles. Overall, parents learned that local MMR vaccination rates were higher than they had expected.
Disclosures. Background. Seasonal vaccination against influenza is the most important public health strategy to prevent influenza morbidity and mortality in children 6-23 months of age. However, influenza immunization uptake in this population remains sub-optimal. While parents look to healthcare professionals (HCPs) for guidance, HCPs may be neither aware of the burden of influenza disease in infants nor familiar with ways to address parental influenza vaccine hesitancy. The objective of this research was to describe the impact of an Information-Motivation-Behavioral Skills model (IMB)-based, accredited, online Continuing Medical Education (CME) program on seasonal influenza vaccination in children 6-23 months of age in Ontario, Canada during the 2016/2017 influenza season.
Methods. A multi-center, randomized, controlled trial was conducted whereby HCPs were randomized to either an accredited IMB-based CME or to routine practice (no CME). The CME addressed influenza burden in young children and identified parental barriers (hesitancy) to influenza vaccination, designed to inform, motivate, and upskill HCPs. All vaccine options were reviewed, including the adjuvanted, trivalent, inactive, influenza vaccine (aTIV). Immunization rates were compared between groups using Pearson's chi-squared and a logistic regression model adjusting for socioeconomic status at the clinic-level.
Results. A total of 68 HCPs were recruited: 33 randomized to the CME group and 35 to routine practice. HCP interactions with parents were evaluated during 628 visits: 292 visits by HCPs in the CME group and 336 by HCPs in the routine practice group. Parents seen by HCPs in the CME group were ~30% more likely to agree to immunize their child with seasonal influenza vaccination compared with parents seen by HCPs in the control group (P = 0.007). The adjusted odds of influenza immunization were 1.5 times higher in the CME group compared with the control group. Children in the CME group were ~20% more likely to receive aTIV compared with children in the control group (P < 0.001).
Conclusion. HCP education with a tailored health behavior uptake model based CME addressing the burden of influenza disease in young children and influenza vaccine hesitancy was associated with a significant increase in influenza immunization.
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